Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Syncona firm Beacon reports encouraging gene therapy trial results
(Sharecast News) - Syncona said in an update on Wednesday that its portfolio company Beacon Therapeutics has reported encouraging six-month interim results from its phase two 'DAWN' trial, marking a key milestone in the development of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP). The FTSE 250 company said the data, presented at the ARVO 2025 annual meeting, showed that patients treated with Beacon's lead asset, 'laru-zova', or laruparetigene zovaparvovec, experienced meaningful improvements in visual function.
Specifically, patients demonstrated early gains in low luminance visual acuity, with greater two- and three-line improvements in treated eyes compared to untreated fellow eyes after six months.
Sustained improvements in retinal sensitivity, measured by microperimetry, were also observed.
Laru-zova was generally well-tolerated, with ocular side effects that were mostly mild or moderate, related to surgical procedures and steroid use, and had largely resolved by the time of reporting.
No serious unexpected adverse reactions, retinal detachments, or cases of endophthalmitis were observed.
Syncona said the publication of the data represented a capital access milestone for Beacon, underscoring the therapeutic potential of the programme and advancing its path towards potential commercialisation.
"We are really pleased with the progress at Beacon - it is fantastic to see continued visual improvements in patients evaluated at the six-month time point in this data update," said Elisa Petris, Syncona Investment Management partner and board director at Beacon Therapeutics.
"We are optimistic as the company progresses enrollment for its phase two and three pivotal study and look forward to seeing data in this crucial programme.
"We see a really differentiated opportunity with this therapy to transform the lives of patients with a devastating retinal blinding condition."
At 1054 BST, shares in Syncona were flat at 90p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
